Master Hemp CBD was created following a rigorous selection process over a period of three years of multiple crosses and field trials. Master Hemp is an 70% sativa and 30% indica plant. The wait is over - Master Hemp high CBD strain is finally here with CBD:THC ratios of 32:1!
Three different lines were utilised in its creation including MMG's high-CBD CD-1 strain, known for its excellent CBD concentrations as well as its strong and sturdy structure. Another component was an old Swiss line which brought greater compactness to both plant and bud. This new strain brings some exotic terpenes to the table and some not normally associated with cannabis. In this way the "entourage effect" is delivered to consumers adding terpenes to the wide range of cannabinoids which include CBC, and THCV alongside the expected CBD and THC, although very low amounts of the latter.
In order to maximise the true potential of this plant it is recommended to grow either outdoors or in a greenhouse environment where it can reach a height of 300 cm. yielding 450 gr/plant with harvest time being either at the end of August or the first week of September at the very latest in northern latitudes. Approximately 30% of plants will turn purple towards the end of florescence.
Indoors can also see growers produce successful crops with the following recommendations; first, it is grown in a 12/12 light/dark scenario throughout its cycle not just during the flowering phase. Secondly, it only requires a light feeding schedule and excessive nutrients will cause lock-out of the same to the plant's detriment. Indoors yields of 400 gr/m2 can be obtained in a 55 - 60 day flowering time.
Terpene production is excellent and is responsible for the intense scents and flavours of incense, lemon and bitter-sweet notes. CBD levels are very high at 12 - 16% while THC production remains extremely low at just 0.3 - 0.5%! This strain will appeal to the therapeutic user or simply to those who wish to enjoy a richly-flavoured smoke or vape without the usual psychoactive response.
|Fabricante||Medical Marijuana Genetics|
|Genética||CD-1 x Swiss Line|
|Tipo de floração||Fotoperíodo|
|Teor THC||0.3 - 0.5%|
|Teor CBD||12 - 16%|
|Rendimento||Indoors: 400 gr/m2; Outdoors: 450 gr/plant|
|Altura da planta||up to 300 cm.|
|Cresce||Estufa, Exterior, Interior|
|Floração||55 - 60 days|
|Período de Colheita||end August - 1st. week September|
|Gosto / Sabor||Amargo, Doce, Incense, Limão|
|Efeito||Calmante, Relaxante, Soothing|
Escrever sua própria revisão
About Medical Marijuana Genetics
In 2014, the founders of Medical Marijuana Genetics first learnt of the therapeutic properties of the cannabis plant whilst desperately treating the symptoms of one of their mother’s late stage pancreatic cancer. Not long after her first dose of cannabis oil, she was able to move around relatively pain free, enabling her to tend to her beloved garden, in the weeks leading up to her death.
The benefit that the cannabis oil had given her was clearly visible to those around her and awoke a passion and deep interest in the use of cannabis as a medicine. Shortly after, the informational website www.medicalmarijuana.co.uk was born and subsequently, a concept to create cannabis strains with the most beneficial therapeutic effects; whilst at the same time raising awareness as to their potential.
Through the organisation's interaction with patients and cannabis communities worldwide, it quickly became apparent that access to cannabis genetics high in cannabinoids other than THC was severely limited. As a result of this, Medical Marijuana Genetics was formed with award winning breeders and caregivers from the Basque region of Spain, with the initial aim of creating a line of CBD dominant cannabis strains.
Using genetics from a number of well established strains, Medical Marijuana Genetics successfully created Candida (CD-1), named after the founder’s mother and meaning ‘bright light’ in Latin. Early laboratory tests of this strain showed very promising results and helped maintain a strong passion in the project. And although Medical Marijuana Genetics have not yet stabilised this strain it shows some consistency in its CBD:THC ratio as well as out-performing any similar strains. To this date, Medical Marijuana Genetics have had results ranging from 20.65% CBD with 0.7% THC to 10.65% CBD to 0.39% THC. These percentages represent the highest known consistent ratios in a CBD-rich seed strain ever created in Europe.
Following the overwhelming success of their first strain, Medical Marijuana Genetics created a further 12 elite strains using Candida as a parent. For their launch, Medical Marijuana Genetics have selected their favourite four of these to release alongside their flagship Candida strain. These have been selected to provide access (within lawful jurisdiction) to the widest range of therapeutics that the cannabis plant, and CBD in particular, has to offer. This includes treatments for symptoms such chronic pain, inflammation, seizures, convulsions, gastro-intestinal disorders, nausea, vomiting, skin conditions, bacterial infections, anxiety, depression, cancer cell growth and much more. All of the strains that are being launched are CBD dominant and have a CBD content of over 8%, but some strains veer towards a 1:1 ratio. At every possible step, Medical Marijuana Genetics have shown averages of their laboratory results as well as the top and bottom end of what has been recorded. We believe this helps give clients the best possible idea of what to expect.
Research continues at Medical Marijuana Genetics to create strains that contain beneficial amounts of CBD as well as other cannabinoids and terpenoids.
Medical Marijuana Genetics are one of a growing number of seedbanks that encourage customers, who are legally permitted to grow, to publish laboratory results of the cannabis they have produced, and to provide detailed feedback of cultivation and medical results.